-+ 0.00%
-+ 0.00%
-+ 0.00%

Evogene loss widens to USD 7.66 million in six months ended June 30, 2026; revenue drops 76% to USD 681,000

PUBT·09/28/2026 20:11:29
Listen to the news
Evogene loss widens to USD 7.66 million in six months ended June 30, 2026; revenue drops 76% to USD 681,000
  • Evogene posted a loss of USD 7.66 million for the six months ended June 30, 2026, little changed year over year.
  • Revenue fell 76% to USD 681,000 from the year-earlier period.
  • Operating loss widened 11% to USD 5.39 million.
  • Loss before taxes on income widened 75% to USD 7.17 million, while net financing results swung to a loss of USD 1.74 million.
  • Cash and cash equivalents declined to USD 9.32 million at June 30, 2026 from USD 12.96 million at Dec. 31, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004636), on September 28, 2026, and is solely responsible for the information contained therein.